ERBB2 and lung carcinoma: Trastuzumab deruxtecan seemed to achieve better treatment outcomes in post-progression lung cancer patients, compared to other HER2-targeted therapies (pyrotinib, afatinib, poziotinib and trastuzumab emtansine) (Table 5).